A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics After Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients With Moderate and Severe Traumatic Brain Injury.
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2016
At a glance
- Drugs SLV 334 (Primary)
- Indications Brain injuries
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Abbott Laboratories
- 04 Jul 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2008-001409-40).
- 25 Aug 2011 Additional lead trial investigator (Juliana Bronzowa) identified as reported by ClinicalTrials.gov.
- 25 Aug 2011 Planned end date changed from 1 Sep 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.